Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04049266 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
A Phase 2 study, sponsored by Kodiak Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 559
- Enrollment target
NCT04049266 is a Phase 2 study that was terminated before completion, run by Kodiak Sciences. The registered enrollment target is 559 participants.
The verdict
NCT04049266, a Phase 2 study, was terminated before completion, sponsored by Kodiak Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 559 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with treatment-naïve neovascular (wet) age-related macular degeneration (nAMD).
Interventions
- OTHER Sham Procedure
- DRUG Aflibercept
- DRUG KSI-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2019-10-08 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04049266
The ClinicalTrials.gov registry entry for NCT04049266 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 559 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kodiak Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham Procedure is the first listed.
NCT04049266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04049266 about?
NCT04049266 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.". This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with treatment-naïve neovascular (wet) age-related macular degene...
What is the current status of trial NCT04049266?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 559 participants. The study started on 2019-10-08. Estimated completion is 2022-04-26.
What interventions are being tested in trial NCT04049266?
The interventions under investigation include: Sham Procedure (OTHER), Aflibercept (DRUG), KSI-301 (DRUG).
Who is sponsoring clinical trial NCT04049266?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.